Safety & Efficacy of Extended Longevity Protocol

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to quantifiably determine if the Extended Longevity Protocol has a significant clinical effect on epigenetic age.

Detailed Description
-----------------
This is a prospective non-randomized clinical study of 15 patients to determine if the safety and effectiveness of the Extended Longevity Protocol's impact on the nine determinant factors of aging can decelerate aging. There is evidence that the Extended Longevity Protocol decelerates aging and the risk of age-related diseases. The aim of this pilot study is to evaluate the safety, efficacy and feasibility of the Extended Longevity Protocol as an effective treatment option to improve clinical care of healthy individual's biological age thus prolonging longevity.

Official Title
-----------------
The Safety and Effectiveness of the Extended Longevity Protocol on the Epigenetic Aging Rate in Healthy Individuals

Conditions
-----------------
Aging

Intervention / Treatment
-----------------
* Dietary Supplement: Extracts found in the Extended Longevity supplements


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 8 Men and 7 Women Must between 55-75 years old Patient must be able to comply with treatment plan and laboratory tests Patients must have adequate immune system function, with no known immunodeficiency disease Exclusion Criteria: Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision No immune system issues or immunodeficiency disease No history of viral illness which could be reactivated by immune downregulation Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke) disease Diagnosis of a transient ischemic attack in the 6 months prior to screening Patients infected with hepatitis, C or HIV Patients with Body Mass Index (BMI) > 40 kg/m2 Presence of active infection Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study Unable or unwilling to provide required blood sample for testing

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Extracts<br>The ingredients found in these serums are all naturally occurring ingredients extracted from a variety of plant species: Pinetonal, Thyvolve, Telogenic, Sentophagy, Inflasolve, Stemegenis, and CMEnhance | Dietary Supplement: Extracts found in the Extended Longevity supplements<br>* Ingredients found in these serums are all naturally occurring, and extracted from a variety of plant species.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Epigenetic Age | Serum epigenetic aging test | Testing will compare the change in results from baseline to 3 months | 
| Epigenetic Age | serum epigenetic aging test | Testing will compare the change in results after completion of intervention with baseline |